|
|
|
|
|
18.08.25 - 07:03
|
Valneva′s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older (GlobeNewswire EN)
|
|
Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. This announcement adds to the adult marketing authorization already received in Canada1 and complements the adolescent label extension received in Europe in April 20252....
|
|
|
|
|
|
|
|
12.08.25 - 07:03
|
Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates (GlobeNewswire EN)
|
|
Saint-Herblain (France), August 12, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its condensed consolidated financial results for the first half of the year, ended June 30, 2025, and confirmed its 2025 financial guidance. The half year financial report, including the condensed consolidated interim financial report and the half year management report, is available on the Company's website (Financial Reports – Valneva)....
|
|
|
|
|
|
|
|
|
|